1. 101 年國人主要死因統計結果
http://health99.doh.gov.tw/txt/HealthyHeadlineZone/HealthyHeadlineDetai.aspx?
TopIcNo=6798 Accessed Oct 22, 2013.
2. 2007 年「臺灣地區高血壓、高血糖、高血脂之追蹤調查研究」
http://health99.hpa.gov.tw/Article/ArticleDetail.aspx?TopIcNo=790&DS=1-life Accessed Oct 22, 2013.
3. 高血脂防治手冊-國人血脂異常診療及預防手冊.行政院衛生福利部國民健康 署, 92 年修訂版
4. 藥物許可證暨相關資料查詢作業網頁. 行政院衛生福利部食品藥物管理署.
http://www.fda.gov.tw/MLMS/(S(dsxxi255g1grajigoqq0pz45))/H0001.aspx.
Accessed Oct 22, 2013.
5. ATC/DDD Index 2013. WHO Collaborating Centre for Drug Statistics
Methodology. http://www.whocc.no/atc_ddd_index/. Published 2013. Accessed Oct 22, 2013.
6. 健保用藥品項查詢作業網頁. 行政院衛生福利部中央健康管理署
http://www.nhi.gov.tw/query/query1.aspx?menu=21&menu_id=713&webdata_id
=3510&WD_ID=851 Accessed Oct 22, 2013.
7. 藥品給付規定：第 2 節 心臟血管及腎臟藥物. 衛生福利部中央健康保險署.
http://www.nhi.gov.tw/webdata/webdata.aspx?menu=21&menu_id=713&WD_ID
=849&webdata_id=2919. Accessed Oct 22, 2013.
8. NICE. CG87 Type 2 diabetes - newer agents (a partial update of CG66): NICE guideline. http://publications.nice.org.uk/type-2-diabetes-cg87. Published 2010.
Accessed Oct 25th, 2013
9. Trilipix (fenofibric acid) Delayed Release Capsules, 45 mg, 135 mg
http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022224_trilipix_toc.cfm
Accessed Oct 22, 2013.10. FDA Drug Safety Communication: Review update of Trilipix (fenofibric acid) and the ACCORD Lipid trial
http://www.fda.gov/drugs/drugsafety/ucm278837.htm#data
11. FDA Endocrinologic and Metabolic Drugs Advisory Committee meeting
http://www.fda.gov/AdvisoryCommittees/Calendar/ucm271163.htm#
12. Henry N. Ginsberg, The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid Trial - What we learn from subgroup analyses. Diabetes care, volume 34, supplement 2, may 2011 S107-108
13. Webb S., Sorensen S. Predicted cardiovascular event reductions with the co-administration of fenofibric acid and low-or moderate-dose statin therapy in
special populations with mixed dyslipidemia Journal of Managed Care Pharmacy 2009; 15(7):594
14. Jacobson T.A. Myopathy with statin-fibrate combination therapy: Clinical considerations Nature Reviews Endocrinology 2009; 5(9):507-518
15. Miranda S, González-Rodríguez Á , García-Ramírez M, Revuelta-Cervantes J, Hernández C, Simó R, Valverde Á M.bBeneficial effects of fenofibrate in retinal pigment epithelium by the modulation of stress and survival signaling under diabetic conditions.J Cell Physiol. 2012 Jun;227(6):2352-62.
16. Trudeau K, Roy S, Guo W, Hernández C, Villarroel M, Simó R, Roy S.b.
Fenofibric acid reduces fibronectin and collagen type IV overexpression in human retinal pigment epithelial cells grown in conditions mimicking the diabetic milieu:
functional implications in retinal permeability.Invest Ophthalmol Vis Sci. 2011 Aug 11;52(9):6348-54.
17. Brautbar A., Covarrubias D., Belmont J., Lara-Garduno F., Virani S.S., Jones P.H., Leal S.M., Ballantyne C.M. Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. Atherosclerosis 2011;219(2):737-742 18. Jacobson T.A. Myopathy with statin-fibrate combination therapy: Clinical
considerations. Nature Reviews Endocrinology 2009; 5(9):507-518
19. Campbell J, Mohiuddin SM. The role of a new formulation of fenofibric acid in the treatment of mixed dyslipidemia in type 2 diabetes. Drugs Today (Barc). 2010 Oct;46(10):757-64.
20. Zhu T, Awni WM, Hosmane B, Kelly MT, Sleep DJ, Stolzenbach JC, Wan K, Chira TO, Pradhan RS. ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans. J Clin Pharmacol. 2009 Jan;49(1):63-71.
21. Goldberg A.C., Bittner V., Pepine C.J., Kelly M.T., Thakker K., Setze C.M., Lele A., Sleep D.J. Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia American Journal of Cardiology 2011;107(6):898-905
22. Davidson M, Rosenson RS, Maki KC, Nicholls SJ, Ballantyne CM, Setze C, Carlson DM, Stolzenbach J. Study design, rationale, and baseline characteristics:
evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial. Cardiovasc Drugs Ther. 2012 Aug;26(4):349-58.
23. Jones PH, Cusi K, Davidson MH, Kelly MT, Setze CM, Thakker K, Sleep DJ, Stolzenbach JC. Efficacy and Safety of.Fenofibric Acid Co-Administered with Low- or Moderate-Dose Statin in Patients with Mixed Dyslipidenria and type 2
Diabetes Mellitus. Am J Cardiovasc Drugs 2010;10 (2): 73-84
24. Robert S. Rosenson & Dawn M. Carlson & Maureen T. Kelly & Carolyn M. Setze
& Boaz Hirshberg & James C. Stolzenbach & Laura A. Williams. Achievement of Lipid Targets with the Combination of Rosuvastatin and Fenofibric Acid in
Patients with Type 2 Diabetes Mellitus. Cardiovasc Drugs Ther 2011; 25:47 – 57 25.
Anne C. Goldberg, Harold E. Bays, Christie M. Ballantyne, T. Kelly, Susan M.
Buttler, Carolyn M. Setze, Darryl J. Sleep, and James C. Stolzenbach.
Efficacy and safety of ABT -335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia.. Am J Cardiol. 2009 Feb 15;103(4):515-22.26. Syed M, Mohiuddin, Cadl J. Pepine, Maureen T. Kelly, Susan M. Buttler,
Efficacy and safety of ABT -335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study. Am Heart J. 2009 Jan;157(1):195-203.
27.
Peter H.Jones, Michael H. Davidson
,Moti L. Kashyap, Maureen T. Kellye, Susan M.
Buttler, Carolyn M. Setze, Darryl J. Sleep, James C. Stolzenbache.
Efficacy and safety of ABT -335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 Atheroscierosis. 2009 may; 204(1): 208-1528. Peter H. Jones, Michael H. Davidson,Anne C. Goldberg, Carl J. Pepine, Maureen T. Kelly, Susan M. Buttler, Carolyn M. Setze, Aditya Lele,Darryl J. Sleep,James C. Stolzenbach. Efficacy and safety of fenofibric acid in combination with a statin in patients with mixed dyslipidemia: Pooled analysis of three phase 3, 12-week randomized, controlled studies. Journal of Clinical Lipidology. 2009; 3: 125-137 29. Geng Q, Ren J, Chen H, Lee C, Liang W. Adverse events of statin- fenofibric acid
versus statin monotherapy: a meta-analysis of randomized controlled trials.
Current Medical Research & Opinion 2013; 29(3): 181 – 188
30. Yang LP, Keating GM. Fenofibric Acid In Combination Therapy in the Treatment of Mixed Dyslipidemia. Am J Cardiovasc Drugs 2009; 9(6): 401-409
31. Filippatos T, Milionis HJ.Treatment of hyperlipidaemia with fenofibrate and related fibrates. Expert Opin Investig Drugs. 2008 Oct;17(I0):1599-614.
32. Zhu T, Awni WM, Hosmane B, Kelly MT, Sleep DJ, Stolzenbach JC, Wan K, Chira TO, Pradhan RS. ABT-335, the choline salt of fenofihric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in 32 humans.
J Clin Pharmacal. 2009 Jan;49(l):63-71
33. Roth EM, Rosenson RS, Carlson DM, Fukumoto SM, Setze CM, Blasetto JW, Khurmi NS, Stolzenbach JC, Williams LA.Efficacy and Safety of Rosuvastatin 5 mg in Combination with Fenofibtic Acid 135 mg in Patients with Mixed
Dyslipidenria -phase 3 Study. Cardiovasc Drugs Ther 2010; 24:421 – 428
34. Eli M. Roth, James M. McKenney, Maureen T. Kelly, Carolyn M. Setze, Dawn M.
Carlson, Alex Gold, James C. Stolzenbach, Laura A. Williams, Peter H. Jones.
Efficacy and Safety of Rosuvastatin and Fenofibric Acid Combination Therapy versus Simvastatin Monotherapy in Patients with Hypercholesterolenria and Hypertriglvceridenria. Am J Cardiovasc Drugs 2010; 10 (3): 175-186
35. Mohiuddin SM, Thakker KM, Setze CM, Kelly MT. Evaluating optimal lipid levels in patients with mixed dyslipidemia following short- and long-term
treatment with fenofiblic acid and statin combination therapy: a post hoc analysis . Current Medical Research & Opinion 2011;27(5):1067 – 1078
36. Zhu T, Ansquer JC, Kelly MT, Sleep DJ, Pradhan RS.Comparison of the Gastrointestinal Absorption and Bioavailability of Fenofibrate and Fenofibric Acid in Humans. Journal of Clinical Pharmacology, 2010;50:914-921
37. Kirchgassler KU, Schiffner-Rohe J, Stahlheber U. Cost effectiveness of
micronised fenofibrate and simvastatin in the short-term treatment of type IIa and type IIb hyperlipidaemia. PharmacoEconomics 1997; 12(2 Pt 2): 237-246.
38. Bergemann R, Brandt A, Siegrist W. Cost-effectiveness study of a lipid-lowering therapy in hyperlipoproteinaemia type IIb and type IV (Frederickson).
PharmacoEconomics 1993; 3(2): 131-139.
39. Haffner SM, Ashraf T. Predicting risk reduction of coronary disease in patients who are glucose intolerant: a comparison of treatment with fenofibrate and other lipid-modifying agents. Managed care interface 2000; 13(3): 52-58.
40. Feher MD, Langley-Hawthorne CE, Byrne CD. Cost-outcome benefits of fibrate therapy in type 2 diabetes. British Journal of Diabetes and Vascular Disease 2003;
3: 124-130.
41. Guay DR. Update on fenofibrate. Cardiovascular drug reviews 2002; 20(4):
281-302.
42. Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE.
Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. Clinical therapeutics 2004; 26(10): 1599-1607.
43. Carrington M, Stewart S. Is fenofibrate a cost-saving treatment for middle-aged individuals with type II diabetes? An economic analysis of the FIELD Study.
International journal of cardiology 2008; 127(1): 51-56.
44. Wessels F. Is fenofibrate a cost-saving treatment for middle-aged individuals with type 2 diabetes? A South African private-sector perspective. Cardiovascular
journal of Africa 2010; 21(1): 43-46.
45. World Health Organization (WHO). The world health report 2002 - Reducing Risks, Promoting Healthy Life.
http://www.who.int/entity/whr/2002/en/whr02_en.pdf. Published 2002. Accessed Oct 25th, 2013
46. 行政院衛生福利部國民健康署. 台灣地區高血壓、高血糖、高血脂盛行率調 查期末報告 http://www.bhp.doh.gov.tw/health91/study-2.htm. Published 2003. Accessed Oct 25th, 2013